SCHEMBL6284517

SCHEMBL6284517

CC(C)Cc1ccccc1CCC(=O)NS(=O)(=O)CCNC(=O)c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MEN1 O00255 3/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
EPHX2 P34913 3/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MCL1 Q07820 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281738 0.89 RAB9A (0.44) KMT2AMEN1RAB9AEPHX2CYP2C9
SCHEMBL6291899 0.82 SMN1; SMN2 (0.44) KMT2ASMN1; SMN2MEN1EPHX2ALDH1A1
SCHEMBL17286598 0.80 KMT2A (0.52) KMT2ASMN1; SMN2MEN1RAB9ANPC1
SCHEMBL6284197 0.79 L3MBTL1 (0.38) SMN1; SMN2RAB9ANPC1CYP2C9CYP2C19
SCHEMBL15625506 0.79 KMT2A (0.59) KMT2ASMN1; SMN2MEN1RAB9ANPC1
SCHEMBL6283252 0.76 MTNR1A (0.39) KMT2AMEN1LMNAALDH1A1MAPT
SCHEMBL6283491 0.74 HTT (0.45) KMT2ASMN1; SMN2MEN1LMNAMAPT
SCHEMBL6279430 0.73 PTGER1 (0.36) KMT2AMEN1RAB9ANPC1LMNA
SCHEMBL4746762 0.70 THRB (0.62) KMT2ASMN1; SMN2MEN1RAB9ANPC1
SCHEMBL4184029 0.70 EPHX2 (0.70) KMT2ASMN1; SMN2MEN1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887903-B1 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. (IT) 2005-05-03 US disclosed
US-6881755-B2 N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing them Dompé S.p.A. (IT) 2005-04-19 US disclosed
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them DOMPE S.P.A. 2003-11-20 US disclosed
EP-1123276-B1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE SPA (IT) 2003-01-08 EP disclosed
EP-1123276-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM Dompe' S.P.A. (IT) 2001-08-16 EP disclosed
WO-2000024710-A1 N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2000-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216392-A1 N - ( 2 - aryl - propionyl ) - sulfonamides and pharmaceutical preparations containing them ELANE, MPO, FPR1 KMT2A 4179/4885SMN1; SMN2 408/4885MEN1 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.